ArticleFrontiers in cellular and infection microbiology2026
Extracellular vesicle microRNA signature as a highly accurate diagnostic biomarker for human brucellosis.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Downregulated Plasma-Derived Extracellular Vesicle MicroRNAs as Novel Biomarkers for Enhanced Tuberculosis Diagnosis.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brucellosis remains an important public health problem globally. Rapid and accurate diagnosis is crucial for the treatment of brucellosis. However, current diagnostic methods for brucellosis are limited, posing significant clinical challenges. Extracellular vesicles (EVs)-derived microRNAs (miRNAs) potentially offer a novel, non-invasive approach for accurate diagnosis of brucellosis. Methods: Small RNA sequencing was conducted to identify candidate miRNAs as potential diagnostic biomarkers in serum-derived EVs from patients with brucellosis and healthy individuals. These miRNA candidates were further validated in serum-derived EVs, serum free of EVs (EVs-free), and serum within an exploratory set and a preliminary validation set using a quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and a logistic regression model to establish and validate the diagnostic signature. Results: The sequencing analysis initially screened and identified a panel of 52 overexpressed miRNAs in serum-derived EVs from patients with brucellosis. Subsequently, qRT-PCR demonstrated that 10 of the top 12 most differentially expressed miRNAs (miR-20a-5p, miR-320a-3p, let-7b-5p, miR-374a-5p, miR-93-5p, miR-186-5p, let-7d-5p, miR-151a-3p, miR-361-5p, and miR-98-5p), effectively distinguished patients with brucellosis from healthy individuals. Among single miRNAs, miR-361-5p (area under the curve [AUC], 0.917 [95% CI, 0.760 -1.000]) has the largest AUC. After logistic regression analysis and qRT-PCR, it was found that a miRNA signature (miR-20a-5p and miR-93-5p) in serum-derived EVs performed more robust in differentiating between patients with brucellosis and healthy individuals (exploratory set: AUC = 1.000; preliminary validation set: AUC = 0.988, 95% CI: 0.949 -1.000). Moreover, there was no significant difference in the expression levels of this miRNA signature in EVs-free and serum. EVs were enriched with miRNAs that are closely associated with Conclusion: MiR-20a-5p and miR-93-5p in serum-derived EVs serve as highly accurate diagnostic biomarkers for brucellosis, offering a rapid and reliable alternative to conventional diagnostic methods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.